Rui Yang, Yunshan Zhang, Xiaoyan Liang, Xueru Song, Zhaolian Wei, Jianqiao Liu, Yezhou Yang, Jichun Tan, Qingxue Zhang, Yingpu Sun, Wei Wang, Weiping Qian, Lei Jin, Shuyu Wang, Yang Xu, Jing Yang, Marie Goethberg, Bernadette Mannaerts, Wen Wu, Zugeng Zheng, Jie Qiao
BACKGROUND: To compare the efficacy and safety of follitropin delta in its individualized fixed-dose regimen with follitropin alfa in a conventional adjustable dosing regimen in Chinese women. METHODS: This was a subgroup analysis of the randomized, multi-center, assessor-blind, non-inferiority trial (GRAPE) including 759 Chinese women (aged 20-40 years) recruited in 16 reproductive medicine clinics in China. Women were randomized in a 1:1 ratio to be treated with either follitropin delta dose based on anti-Müllerian hormone (AMH) and body weight or conventional dosing with follitropin alfa following a gonadotropin-releasing hormone (GnRH) antagonist protocol...
October 4, 2022: Reproductive Biology and Endocrinology: RB&E